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Conjugated Linoleic Acid Does Not Improve
Insulin Tolerance in Mice*
Kimberly M. Hargrave,† Michael J. Azain,‡ Stephen D. Kachman,† and Jess L. Miner†
Abstract
HARGRAVE, KIMBERLY M., MICHAEL J. AZAIN,
STEPHEN D. KACHMAN, AND JESS L. MINER.
Conjugated linoleic acid does not improve insulin tolerance
in mice. Obes Res. 2003;11:1104–1115.
Objective: To determine if the addition or removal of di-
etary conjugated linoleic acid (CLA) would alter insulin
tolerances in mice from two genetic lines.
Research Methods and Procedures: High metabolic rate
(MH) and low metabolic rate (ML) mice were assigned to
consume 1) a control diet ad libitum, 2) a control diet at a
restricted intake, or 3) a diet containing 1% CLA ad libitum.
After 9 weeks, an insulin tolerance test was conducted, and
a portion of the mice were killed. All remaining mice
consumed the control diet ad libitum. Insulin tolerance tests
were conducted 11 and 32 days after the diet change, and
mice were killed 3 days after each test. Body fatness, fat pad
weights, and serum insulin concentrations of mice were
determined at each time-point. Two follow-up experiments
were also conducted.
Results: Restricted mice had insulin sensitivities not differ-
ent than control mice. CLA-fed MH mice in experiment 1
were resistant (p  0.001) to insulin on each day measured.
CLA-fed ML mice were slightly resistant (p  0.08) to
exogenous insulin on day 0 of recovery and not different
from control mice on day 11 or 32. Glucose response to
insulin in MH mice fed CLA in experiments 2 or 3 did not
differ from control mice.
Discussion: Mice fed CLA did not have improved insulin
tolerances compared with control mice. In some cases,
dietary CLA may cause insulin resistance. MH mice seem
more sensitive to CLA than ML mice.
Key words: mice, insulin tolerance, body fat, conjugated
linoleic acid
Introduction
Conjugated linoleic acid (CLA)1 refers to linoleic acid
isomers with conjugated double bonds. Some are formed
naturally through biohydrogenation of linoleic acid by mi-
croorganisms in the stomach of ruminant animals. CLA is
therefore found in the fat associated with the meat and milk
of such animals. Dietary CLA may benefit human health
because of anticancer (1–3), antiobesity (4,5), anti-athero-
sclerosis (6,7), and antidiabetes effects (8,9).
CLA is a ligand for the peroxisome proliferator-activated
receptors (PPARs) (10,11). PPAR subtypes  and  are
transcription factors that regulate genes involved in glucose
and lipid metabolism. CLA’s proposed antidiabetic effect
has been attributed to activation of PPAR. Zucker diabetic
fatty (ZDF) fa/fa rats fed CLA exhibited improved insulin
action as measured by a smaller increase in blood glucose
after administration of exogenous glucose (8). Dietary CLA
also reduced plasma insulin, free fatty acid, and glucose
concentrations, and increased PPAR activity and aP2 (a
PPAR-responsive gene) mRNA abundance. Similar ef-
fects were observed in rats fed the synthetic PPAR ligand,
troglitazone, a known insulin-sensitizing drug (8). Ryder et
al. (9) confirmed the above results, again in ZDF rats, and
implied that the trans-10,cis-12 CLA isomer is the isomer
responsible for the apparent improved insulin sensitivity.
However, these antidiabetic effects have not been demon-
strated in other species or other rat strains. In contrast,
consumption of CLA by mice increased plasma insulin
concentrations and impaired insulin tolerance (12,13). Di-
etary CLA did not influence basal insulin concentrations or
glucose use in lactating dairy cows (14) or OLETF rats (15),
and the trans-10,cis-12 isomer reduced glucose incorpora-
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tion into total lipid in cultured human preadipocytes (16).
Furthermore, in humans, supplementation with a mixture of
CLA isomers has not altered plasma glucose or insulin
concentrations (17) in abdominally obese men. The trans-
10,cis-12 isomer, however, has reduced insulin sensitivity
in nondiabetic men at risk for cardiovascular disease (18).
Given these reports, the potential antidiabetic effects of
dietary CLA are questionable.
Our hypotheses were that, although insulin tolerance
would not be improved by CLA consumption, per se, the
reduction in body fat caused by CLA would enhance insulin
tolerance once CLA was removed from the diet.
Research Methods and Procedures
Mouse Lines and Diets
We used mouse lines that were developed by divergent
genetic selection on metabolic rate: high metabolic rate
(MH) and low metabolic rate (ML) mice. MH1, MH2, and
MH3 exhibit basal energy expenditure that is 50% greater
than that of ML1, ML2, and ML3 (19). MH mice typically
consume more feed and are leaner than the ML mice but do
not differ in body weight (20,21). MH or ML mice do not
exhibit diabetic tendencies, nor do the lines differ in blood
glucose or plasma insulin levels (unpublished observations).
Dietary CLA causes a similar body fat loss in both MH and
ML mice (22,23).
Mice were fed a purified base diet (AIN-93G) containing
(g/kg) isolated soy protein 200, cornstarch 395.42, dextron-
ized cornstarch 132, sucrose 100, cellulose 50, soy oil 70,
AIN-93G mineral mix 35, AIN-93G vitamin mix 10, L-
cystine 2.54, L-methionine 2.54, and choline bitartrate 2.5
(Dyets, Inc., Bethlehem, PA). Soy protein was used instead
of casein to preclude presence of CLA in the base diet. The
CLA mixture contained approximately equal concentrations
each of the cis-9,trans-11 and the trans-10,cis-12 isomers
and was provided by BASF (Offenbach a.d. Queich, Ger-
many). CLA was included in the diets to provide 1% of the
diet as CLA isomers and replace soy oil (w/w). The fatty
acid profiles of the oil sources (soy and CLA) are provided
in Table 1.
Animal Protocol
Experimental procedures were approved by the Univer-
sity of Nebraska Institutional Animal Care and Use Com-
mittee. Mice were housed either three per cage (experiment
1, weeks 1 to 6) or individually (experiment 1, weeks 7 to
Figure 1: Timeline of events in animal procedure, experiment 1. From day 0 onward, all mice consumed the basal diet ad libitum.
Table 1. Fatty acid profile of dietary fat sources








CLA cis-9, trans-11 0.00 27.83
CLA trans-10, cis-12 0.00 26.93
CLA other isomers 0.00 6.92
C18:3 8.01 0.00
* Fatty acid concentrations reported as percent of total fatty acids.
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14; experiment 2; and experiment 3) at 22 °C, under a
photoperiod of 12 hours light, 12 hours dark.
Experiment 1. See Figure 1 for the timeline of events in
this experiment. Seventy-five male mice (33 MH1, 42 ML1;
9 weeks of age) were blocked by litter and randomly as-
signed to three experimental treatments: control, base diet
offered ad libitum; restricted, base diet offered at 65% to
70% of the intake of the control mice; CLA, base diet 1%
CLA isomers offered ad libitum. The restricted group was
targeted to attain body fatness equal to the CLA group. This
would allow, during the recovery phase, an insulin tolerance
comparison between mice previously fed CLA and not fed
CLA but at similar body fatness.
Feed intake and body weight were measured weekly.
Feed intake was measured as disappearance from glass jars
equipped with a cylindrical stainless steel screen attached to
a small-holed lid. No feed spillage was observed. After 9
weeks, 54 mice underwent an insulin tolerance test. Three
days later, 18 of them were killed; blood glucose was
measured, and serum, epididymal fat pads, and livers were
collected. A body fat index was calculated: body fat in-
dex  [(total collected fat pad weight  total ether extract
of the remaining carcass)/total body weight]  100. All
remaining mice were offered the basal diet ad libitum from
this time forward. Eleven days after the diet change, 36
mice underwent a second insulin tolerance test, and 3 days
later, 21 mice were killed, and tissues were collected as
before. Thirty-two days after the diet change, the remaining
mice underwent a third insulin tolerance test and were killed
3 days later. Tissues from these mice were also collected as
described above.
Experiment 2. Because the response to CLA in experi-
ment 1 differed between MH1 and ML1, we again tested the
effect of dietary CLA on insulin tolerance in experiment 2.
In this experiment, we used a different line of MH mice,
MH3. Twenty-four male MH3 mice (12 weeks of age) were
blocked by weight and randomly assigned to treatment:
control, base diet offered ad libitum; CLA, base diet  1%
Figure 2: Effect of diet on feed intake and body weight, experiment 1. MH, MH1 (mouse line selected for high metabolic rate); ML, ML1
(mouse line selected for low metabolic rate); control, 7% soy oil diet; restricted, control diet at 65% to 70% intake of control mice; CLA,
6% soy oil  1% CLA diet. Arrow indicates switch to all mice consuming control diet ad libitum. The experiment started with n  10 to
14 mice per line per diet. (A) Feed intake, grams per day. #Main effect of line, p  0.05. *Main effect of diet, p  0.05. **Line  diet
interaction, p  0.05. (B) Body weight, grams. #Main effect of line, p  0.05. *Main effect of diet, p  0.05. **Line  diet interaction,
p  0.05.
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CLA isomers offered ad libitum. Feed intake and body
weight were measured weekly, and after 6 weeks, the mice
underwent an insulin tolerance test. All mice were then
offered the control diet ad libitum for 24 days, and a second
insulin tolerance test was conducted. No tissues were col-
lected from mice in this experiment.
Experiment 3. Twenty-four male MH1 mice (12 weeks of
age) were blocked by weight and randomly assigned to
treatment: control, base diet offered ad libitum; CLA, base
diet 1% CLA isomers offered ad libitum. Feed intake and
body weight were measured weekly, and after 6 weeks, the
mice underwent an insulin tolerance test. The following
day, the mice were killed, and the retroperitoneal and epi-
didymal fat pads were weighed and collected.
Insulin Tolerance Tests
Mice were fasted for 3 hours and then bled from the tail
tip to obtain a preinjection glucose concentration. Glucose
was measured immediately using the SureStep Glucose
Monitor (Lifescan, Milpitas, CA). Insulin (0.5 mU/kg body
weight diluted in 0.9% saline) was injected intraperitone-
ally, subsequent blood samples were taken from the tail tip,
Figure 3: Effect of diet on body fatness, as measured by body fat index (A) and epididymal (EPI) fat pad weight (B) of mice fed control
or CLA-containing diets for 9 weeks, followed by a control diet for 0, 14, and 35 days, experiment 1. Body fat index is calculated as total
ether extract  fat pad weights, divided by body weight, multiplied by 100. MH, MH1 (mouse line selected for high metabolic rate); ML,
ML1 (mouse line selected for low metabolic rate); control, 7% soy oil diet; restricted, control diet at 65% to 70% intake of control mice;
CLA, 6% soy oil  1% CLA diet. Day 0, n  3 mice per line per diet; day 14, n  1 to 5 mice per line per diet; day 35, n  5 to 6 mice
per line per diet. Error bars represent SEM. abDifferent letters represent differences within line, p  0.05. cMain effect of line, p  0.05.
CLA and Insulin Tolerance, Hargrave et al.
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and glucose was measured at 30, 60, 90, and 120 minutes
postinjection in experiment 1. Experience gained in exper-
iment 1 indicated that it would be possible to collect blood
at closer intervals; therefore, in experiments 2 and 3, blood
was collected at 10, 20, 30, 60, and 120 minutes after
injection. Preinjection glucose concentration and the change
in glucose from preinjection to 30 minutes postinjection
were subjected to tests of treatment effect as described
below.
Fatty Acid Analysis
Total fatty acids from epididymal fat pads and livers from
mice in experiment 1 were extracted and methylated ac-
cording to the Park and Goins method (24), and fatty acid
methyl esters were analyzed by gas chromatography as
previously reported (25).
Basal Insulin Analysis
Insulin was measured in serum samples from mice in
experiment 1 using the Linco Rat Insulin Radioimmunoas-
say and Sensitive Rat Insulin RIA Kits (Linco Research,
Inc., St. Charles, MO).
Data Analyses
Data were analyzed by day using a mixed model with
line, diet, and line  diet as fixed effects and litter nested
within line as a random effect. F tests, least-squares means,
and SEMs were calculated using the mixed procedure of
SAS (SAS Institute Inc., Cary, NC).
Results
Feed Intake and Body Weight
As expected, ML1 mice consumed less feed ad libitum
than did MH1 mice (p  0.05; Figure 2A). There was no
effect of CLA on feed intake in experiment 1. However,
feed intake was reduced (p  0.05) in CLA-fed mice at
week 1 (3.87 vs. 3.54 g/d) in experiment 2 and at weeks 5
and 6 (4.04 vs. 3.71 and 4.13 vs. 3.68 g/d, respectively) in
experiment 3 (data not shown). The only dietary effect on
body weight was that feed restriction reduced body weight
(p  0.05; Figure 2B).
Tissue Weights and Body Composition
In experiment 1, mice that were feed restricted or fed
CLA were leaner (p 0.05) than control mice, as measured
by epididymal fat pad weight and the body fat index,
regardless of genetic line (Figure 3). After 14 days of
recovery from CLA or restriction, MH1 mice previously
Figure 4: Effect of diet on fat pad weight of mice fed control or
CLA-containing diets for 6 weeks, experiment 3. MH, MH1
(mouse line selected for high metabolic rate); control, 7% soy oil
diet; CLA, 6% soy oil 1% CLA diet. N 12 mice per diet. Error
bars represent SEM. abDifferent letters within fat pad represent
differences, p  0.001.
Figure 5: Effect of diet on basal blood glucose and serum insulin
concentrations at death of mice fed control or CLA-containing
diets for 9 weeks, followed by control diet for 0, 14, and 35 days,
experiment 1. Line  diet  not significant; therefore, bars rep-
resent least squares means of glucose and insulin in mice from
both genetic lines (MH1 and ML1). Control, 7% soy oil diet;
restricted, control diet at 65% to 70% intake of control mice; CLA,
6% soy oil  1% CLA diet. (A) Day 0 of recovery. (B) Day 14 of
recovery. (C) Day 35 of recovery. Day 0, n  6 mice per diet; day
14, n  3 to 6 mice per diet; day 35, n  7 to 10 mice per diet.
Error bars represent SEM. abDifferent letters represent differences
in glucose, p  0.05. cdDifferent letters represent differences in
insulin, p  0.05.
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restricted or fed CLA remained leaner (p  0.05) than
controls. ML1 mice previously fed CLA had lighter (p 
0.05) epididymal fat pads than control mice, but there were
no differences (p  0.05) in body fat index. After 35 days
of recovery, all mice within a line were similar in body
fatness. MH1 mice had higher (p  0.05) body fat indexes
on day 0 and heavier (p  0.05) epididymal fat pads on day
35 than ML1 mice. In experiment 3, CLA-fed mice had
lighter (p  0.001) retroperitoneal and epididymal fat pads
than control-fed mice (Figure 4).
Basal Glucose and Insulin
The line diet interaction was not significant on any day
for basal glucose or insulin. Therefore, the data are reported
as the least-squares means for diet, averaged over the two
lines (Figure 5). In experiment 1, the concentration of
glucose in blood collected by cardiac puncture at death on
day 0 was less in feed-restricted mice (p  0.05) than in
control or CLA-fed mice. There were no differences in
cardiac blood glucose concentration at death on days 14 or
35.
Seventeen serum samples (evenly distributed between
treatments) were not analyzed for insulin because, at the
lowest dilution recommended by the manufacturer, the ra-
dioactive counts were below the level of detection for this
assay. All remaining samples were assayed according to the
manufacturer’s directions. On day 0, CLA-fed mice exhib-
ited a greater (p 0.05) concentration of serum insulin than
did restricted mice (Figure 5). On day 14, the ranking of
CLA  control  restricted was not significant. On day 35,
previously restricted mice again had the lowest (p  0.05)
serum insulin concentration, and there was no difference
between CLA and control mice.
Blood Glucose Response to Insulin
A graph showing the change in blood glucose after an
insulin injection in mice on day 0 in experiment 1 is shown
in Figure 6. The 30-minute postinjection glucose measure-
ment was chosen as the time-point to use for statistical
analysis of the change in glucose, because at this time the
blood glucose concentration was nearing the maximal drop
but had not yet begun to rebound. The effect of CLA on
serum glucose concentration at the 30-minute sampling is
representative of its effect at the other sampling times.
Similar to cardiac blood, the basal glucose concentrations
in tail blood differed on day 0 in experiment 1 (Figure 7).
MH1 mice on the control treatment had a greater (p 0.05)
concentration of glucose than did CLA-fed mice, which had
a greater (p  0.05) concentration of glucose than restricted
mice (Figure 7). ML1 mice on the control and CLA treat-
ments had similar glucose concentrations, which were
greater (p 0.05) than those found in restricted mice. There
were no differences in preinjection glucose values on days
11 or 32. In experiments 2 and 3, there were no differences
(p  0.05) in preinjection glucose concentration (Figure 8).
In experiment 1, in no instance was there a difference in
the change in glucose at 30 minutes between control and
restricted mice. MH1 mice fed CLA exhibited an unex-
pected pattern. Their blood glucose concentration was in-
creased at 30 minutes after the insulin injection on each day
(Figure 7). This pattern was not observed in the ML1 mice,
although on day 0, there was a trend (p  0.08) for the
CLA-fed mice to have a smaller drop in blood glucose than
the control or restricted mice. The MH3 and MH1 mice used
in experiments 2 and 3, respectively, did not respond in the
same manner as those used in experiment 1, because there
were no differences (p  0.05) in the change in glucose at
30 minutes in control or CLA-fed mice in either experiment
(Figure 8).
Fatty Acid Profile
The fatty acid profiles of epididymal fat pads from ex-
periment 1 were analyzed by gas chromatography. On day
0 of recovery, restricted mice had an increased (p  0.05)
percentage of fatty acids that were saturated (16:0 and 18:0)
Figure 6: Change in glucose after insulin injection in mice on day 0 (n  9 per line per diet), experiment 1. Error bars represent SEM.
CLA and Insulin Tolerance, Hargrave et al.
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and a decreased (p  0.05) concentration of linoleic (18:2)
and linolenic acids (18:3; Table 2). These changes in the
relative concentration of the fatty acids caused by feed
restriction were maintained at least 35 days after the end of
the restricted period. Mice fed CLA also showed changes in
the fatty acid profile of their fat pads. CLA addition to the
diet decreased (p  0.05) the concentration of the mono-
unsaturated palmitoleic acid (16:1) and the essential poly-
unsaturated linolenic acid (18:3), whereas it increased (p 
0.05) the concentration of both the cis-9,trans-11 and trans-
10,cis-12 CLA isomers on day 0. After 14 d of receiving a
diet lacking CLA, mice previously fed CLA exhibited only
a trend (p  0.10) for increased CLA isomers, and by day
35, there were no differences in the fatty acid concentrations
between control and CLA-fed mice.
Livers from mice in experiment 1 also were analyzed for
fatty acids. Similar to the results observed in adipose tissue,
feed restriction caused a decrease (p 0.05) in the essential
Figure 7: Effect of diet on preinjection and 30-minute postinsulin injection blood glucose concentrations of mice fed control or
CLA-containing diets for 9 weeks, followed by control diet for 0, 11, and 32 days, experiment 1. MH, MH1 (mouse line selected for high
metabolic rate); ML, ML1 (mouse line selected for low metabolic rate); control, 7% soy oil diet; restricted, control diet at 65% to 70% intake
of control mice; CLA, 6% soy oil  1% CLA diet. (A) Day 0 of recovery. (B) Day 11 of recovery. (C) Day 32 of recovery. Day 0, n 
9 mice per line per diet; day 11, n  6 mice per line per diet; day 32, n  5 to 6 mice per line per diet. abcDifferent letters represent
differences in baseline glucose, within mouse line, p 0.05. deDifferent letters represent differences in the change in glucose at 30 minutes,
within mouse line, p  0.05.
CLA and Insulin Tolerance, Hargrave et al.
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polyunsaturated fatty acids, linoleic acid (day 0) and linole-
nic acid (day 14; Table 3). However, these results were not
maintained through day 35 in the liver. CLA supplementa-
tion caused a reduction (p  0.05) in linolenic acid on day
14. Also, on day 35, MH1 mice that had previously been fed
CLA had reduced (p  0.05) stearic acid (C18:0) and
increased (p  0.05) oleic acid (C18:1) concentrations.
Unlike adipose tissue, on no day was the concentration of
either CLA isomer increased in the liver compared with
control mice.
Discussion
Dietary CLA has been touted as having antidiabetic prop-
erties based on data collected using ZDF fa/fa rats (8,9), but
the same effects have not been observed in other species,
including humans (12–14,18). Nondiabetic Zucker rats have
previously not responded to dietary CLA in a typical man-
ner; lean rats fed CLA lost body fat, whereas obese rats fed
CLA had heavier fat pads than non–CLA-fed rats (26).
Therefore, ZDF rats may not be an adequate model for the
effect of CLA for other species or genetic lines of rats.
Genetic lines of mice that have been selected for differing
metabolic rates and energy expenditure were used in this
study. Terpstra (27) stated that mice may be more respon-
sive to CLA-induced body fat loss than humans because of
a greater relative effect on energy expenditure. We therefore
used the MH and ML mouse lines to determine if differing
metabolic rates would influence the response to CLA. The
effect of CLA on insulin tolerance seemed to be greater in
the MH mice. The CLA-induced effect was not consistent
with that observed in the Zucker rats (8,9). In the present
study, mice fed CLA were either equally responsive or were
less responsive to exogenous insulin. Mice in this study
were supplemented with CLA for 9 weeks, whereas the
Zucker rats in the previously cited literature were fed CLA
for 2 weeks. The difference in length of CLA feeding is not
likely to explain the opposing observations; however,
DeLany et al. (12) observed numeric increases in plasma
insulin concentration in CLA-supplemented mice in as little
as 2 weeks and significant increases in 39 days. We also
determined that reduced body fatness alone did not induce
the changes in insulin tolerance seen in CLA-fed mice.
Dietary supplementation of 1% CLA in this study re-
sulted in a significant loss of body fat in both genetic lines
of mice, as has previously been shown (23,28). Unlike
results reported previously (12,13), dietary CLA did not
increase the serum insulin concentration in 3-hour fasted
mice. The effect of CLA on insulin concentration seems to
be greater in fed mice than fasted mice (13), and the mice
being fasted in the current study may account for the lack of
effect of CLA on serum insulin concentration.
Tsuboyama-Kasaoka et al. (13) observed an increased
preinjection concentration of glucose and a reduced drop in
glucose after insulin injection in mice fed CLA for 9 weeks.
We report here no increase in blood glucose before the
insulin injection after 9 weeks of CLA supplementation;
CLA-fed MH mice actually had reduced blood glucose
preinjection compared with control mice. ML mice fed
CLA did exhibit a reduced drop in glucose compared with
the control or restricted mice, similar to that observed by
Tsuboyama-Kasaoka et al. (13). The MH mice that were fed
CLA exhibited even less sensitivity to the exogenous insu-
lin, resulting in an increase in blood glucose at 30-minutes
postinjection. The MH mice typically have greater locomo-
tor activity than ML mice, which contributes to the differ-
ences in body fatness in these lines (29,30). It is possible
that the MH mice are more prone to react to the stress of the
insulin tolerance test, and therefore, release a larger amount
of epinephrine, which would increase blood glucose and
amplify the CLA-induced insulin resistance.
It is interesting to note that the increases in body fat in the
mice from days 0 to 35 correspond with the clearance of the
CLA isomers from the epididymal fat pad. CLA isomers
Figure 8: Preinjection and 30-minute postinsulin injection blood
glucose concentrations of mice fed control or CLA-containing
diets for 6 weeks, followed by control diet for 0 or 24 days,
experiments 2 and 3. Control, 7% soy oil diet; CLA, 6% soy oil 
1% CLA diet. N  12 mice per diet in each experiment. (A) Day
0 of recovery, mouse line MH3, experiment 2. (B) Day 24 of
recovery, mouse line MH3, experiment 2. (C) Day 0 of recovery,
mouse line MH1, experiment 3.
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have been reported to be cleared from adipose tissue within
4 weeks of CLA removal from the diet (31). This is con-
sistent with the results from this study, because at 14 days
of recovery, there were still small amounts of CLA present
in the fat pad, but by day 35, the level of the isomers was not
different from those found in the control mice. However, the
changes in insulin tolerance seem to not be dependent on the
isomers’ presence in the fat pad or liver. By 11 days of
recovery, the ML mice previously fed CLA had glucose
responses to insulin not different from controls, even though
Table 2. Effect of diet on fatty acid profile of epididymal fat, experiment 1*
Fatty acid†
MH ML
SEMCon Res CLA Con Res CLA
Day 0‡
C14:0 0.88b 1.42a 0.85b 0.87b 1.43a 0.74b 0.06
C16:0 18.14c 24.79a 19.80bc 17.86c 23.91ab 18.67c 0.93
C16:1 4.62a 5.64a 3.05bc 4.28ab 4.08abc 2.59c 0.35
C18:0 2.15b 4.07ab 1.97b 2.20b 5.78a 1.86b 0.57
C18:1 31.13 32.65 34.33 33.01 35.11 36.04 0.96
C18:2 39.83a 29.07b 37.32a 39.41a 28.01b 37.04a 1.06
CLA, c9,t11 0.45bc 0.55b 0.97a 0.16c 0.02d 1.02a 0.07
CLA,t10,c12 0.03b 0.02b 0.45a 0.05b 0.04b 0.44a 0.04
C18:3 2.53a 1.88bc 1.56de 2.32ab 1.69cd 1.11c 0.20
C20:4 0.11b 0.04b 0.01b 0.00b 0.32a 0.03b 0.03
Day 14‡
C14:0 0.88b 1.25a 0.80b 0.83b 1.19a 0.82b 0.06
C16:0 15.21c 21.06a 17.07bc 19.18b 24.09a 18.34b 0.82
C16:1 5.86ab 6.28ab 4.20b 4.71b 6.83a 5.00ab 0.53
C18:0 1.51d 4.37a 1.66cd 2.04c 2.65b 1.52d 0.15
C18:1 32.18 37.50 32.11 32.10 30.44 32.09 1.14
C18:2 41.33a 27.78b 40.64a 38.61a 31.95b 38.02a 1.55
CLA,c9,t11 0.19 0.00 0.52 0.32 0.16 0.49 0.12
CLA,t10,c12 0.00 0.00 0.12 0.00 0.00 0.08 0.03
C18:3 2.60 1.76 2.77 2.38 2.78 2.58 0.23
C20:4 0.00 0.00 0.12 0.04 0.13 0.20 0.05
Day 35‡
C14:0 0.84b 1.04a 0.82b 0.75b 1.03a 0.80b 0.04
C16:0 16.35c 19.99ab 18.29bc 17.78c 21.49a 18.02bc 0.66
C16:1 4.85b 7.14a 4.88b 4.22b 6.78a 4.96b 0.37
C18:0 1.75b 2.59a 1.87b 2.16ab 2.52a 1.75b 0.18
C18:1 31.97 31.26 31.32 32.28 30.91 31.25 0.79
C18:2 41.02a 35.03c 40.16ab 40.49ab 32.18d 38.31b 0.82
CLA,c9,t11 0.39a 0.22ab 0.36ab 0.17b 0.11b 0.32ab 0.07
CLA,t10,c12 0.00 0.00 0.00 0.00 0.00 0.03 0.02
C18:3 2.50 2.83 2.87 2.39 4.53 4.39 1.08
C20:4 0.03c 0.13ab 0.19a 0.07bc 0.09abc 0.09bc 0.03
* Different letters within a row represent differences (p  0.05).
† Fatty acids were analyzed by gas chromatography and expressed as a percent of total fatty acids.
‡ Day, day of recovery.
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their fat pad still contained some CLA. Conversely, MH
mice remained insulin resistant after 35 d of recovery even
though there were no differences in the percentage of fatty
acids that were CLA isomers compared with the control
mice. Accumulation of CLA in liver tissue was not signif-
icant in this study, indicating that CLA stores in the liver are
not necessary for either a reduction in body fat or altered
insulin tolerance. It is possible that CLA stores in other
tissues contributed to the insulin resistance observed in the
MH mice. Park et al. (31) reported that the level of CLA
isomers in muscle did not return to control levels until 8
weeks after CLA removal.
CLA reduces the mRNA abundance and protein activity
of hepatic stearyl-CoA desaturase (32–34). Stearyl-CoA
desaturase is responsible for the conversion of stearic acid
(C18:0) to oleic acid (C18:1). In this study, we did not
detect significant differences in these fatty acids on day 0.
There is, however, a numeric increase in stearic acid and
reduction in oleic acid in MH1 mice fed CLA compared
with controls. By day 35, this has reversed so that there is
significantly less stearic acid and more oleic acid in the liver
of mice that had been supplemented with CLA. This trend
is not observed in the ML1 mice and may explain part of the
different responses to CLA observed in the two lines.
Table 3. Effect of diet on fatty acid profile of liver, experiment 1*
Fatty acid†
MH ML
SEMCon Res CLA Con Res CLA
Day 0‡
C16:0 23.95 23.62 23.26 23.67 25.64 23.24 1.028
C16:1 4.16 2.15 1.77 1.25 1.28 1.28 0.832
C18:0 9.95 11.95 12.61 13.35 12.24 12.82 1.252
C18:1 20.95 18.40 16.09 14.03 16.48 13.66 2.490
C18:2 27.10a 22.09b 24.71ab 27.11a 25.09ab 23.55ab 1.307
CLA,c9,t11 0.17 0.37 0.44 0.11 0.13 0.58 0.155
CLA,t10,c12 0.03 0.00 0.00 0.00 0.00 0.07 0.033
C18:3 0.95 0.63 0.67 0.75 0.66 0.52 0.125
Day 14‡
C16:0 21.30 20.77 22.23 23.53 22.81 23.22 0.971
C16:1 2.12ab 1.14b 2.74a 2.43ab 2.31ab 3.03a 0.383
C18:0 10.11bc 14.75a 10.96bc 9.63bc 11.11b 8.95c 0.870
C18:1 15.80 13.31 19.29 18.88 18.62 20.40 2.069
C18:2 30.13 25.85 26.62 26.95 24.77 25.71 1.513
CLA,c9,t11 0.53 0.43 0.37 0.53 0.51 0.55 0.097
CLA,t10,c12 0.00 0.00 0.00 0.05 0.04 0.09 0.054
C18:3 1.40a 0.57b 0.94b 1.10ab 0.91b 1.03b 0.138
Day 35‡
C16:0 24.13 23.91 25.14 24.04 25.07 24.70 0.673
C16:1 2.29ab 2.54ab 3.20a 2.21b 1.71b 2.13b 0.333
C18:0 11.72a 11.47ab 9.43b 12.12a 12.75a 12.12a 0.760
C18:1 15.62b 16.22b 21.59a 16.24b 15.46b 15.75b 1.301
C18:2 30.34 28.02 26.62 28.61 28.23 27.24 1.083
CLA,c9,t11 0.00 0.14 0.00 0.11 0.00 0.11 0.066
CLA,t10,c12 0.00 0.08 0.00 0.00 0.00 0.03 0.035
C18:3 1.09a 1.16a 1.14a 0.63b 0.89ab 0.91ab 0.137
* Different letters within a row represent differences (p  0.05).
† Fatty acids were analyzed by gas chromatography and expressed as a percent of total fatty acids.
‡ Day, day of recovery.
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No differences in insulin tolerance were observed be-
tween the control or CLA-fed MH mice in experiments 2 or
3. CLA-fed mice from experiment 3 did have reduced fat
pad weights, indicating that CLA was present in the diet and
able to induce a loss of body fat. It is possible that the
feeding period of CLA was not long enough in these ex-
periments to induce a change in insulin tolerance. The
length of the treatment period was reduced from 9 weeks in
experiment 1 to 6 weeks in experiments 2 and 3 to maintain
the same age of the mice at the first insulin tolerance test.
Increases in plasma insulin concentrations have been ob-
served after 6 to 8 weeks of CLA supplementation (12).
Additionally, mice from experiment 2 were from the MH3
line, unlike the mice from experiment 1, which were from
MH1. Because the lines were selected independently, there
may be differences in the mechanism behind the increased
metabolic rate in the different lines that affects response to
dietary CLA.
Previously, rats pair-fed to the intake of CLA-fed rats
exhibited reduced blood glucose and plasma insulin con-
centrations and an intermediate improvement in whole-body
glucose tolerance similar to the CLA-fed rats (9). In this
study, the restricted mice exhibited reduced blood glucose
and serum insulin concentrations compared with either the
control or CLA mice; however, this did not result in a
change in glucose response to insulin.
In conclusion, mice fed CLA did not exhibit improved
insulin tolerances; they exhibited either no change in insulin
tolerance or developed a resistance to insulin after dietary
supplementation with CLA. It also seems that mice with a
higher metabolic rate may be more sensitive to CLA-in-
duced changes in insulin sensitivity. Furthermore, reducing
the feed intake, and consequently the body weight and body
fatness, of mice did not alter the insulin tolerance, as mea-
sured by the change in blood glucose after an insulin injec-
tion. It is unclear why the apparent species or genetic
differences in CLA-induced changes in glucose metabolism
exist, and until the effects of CLA on insulin sensitivity in
humans is more completely studied, CLA should not be
recommended as an antidiabetic food supplement.
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